Lixisenatide as a treatment for early Parkinson’s disease progression

[Farooqji]

In this randomized controlled trial, lixisenatide reduced motor disability progression in Parkinson’s patients.

2. Individuals in the lixisenatide group experienced greater gastrointestinal side effects rates than individuals in the placebo group.

Evidence Rating Level: 1 (Excellent)

2minutemedicine.com/lixisen...